Bangladesh Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position

Sign up to download the Bangladesh Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

Bangladesh Pharmaceuticals & Healthcare Report
Product Price

BMI View: Bangladesh's long-term potential will be the central factor shaping its attractiveness to multinational drugmakers. Rising household incomes - coupled with improving healthcare access, driven largely by the influx of private hospitals into the country - bode well for sustained strong growth from a low base. In the short term, growth opportunities lie largely in driving higher volumes and are concentrated in major cities such as Dhaka and Chittagong.

Headline Expenditure Projections

  • Pharmaceuticals: BDT171.6bn (USD2.2bn) in 2015 to BDT190.8bn (USD2.4bn) in 2016; +11.2% in local currency terms and +8.8% in US dollar terms. Forecast revised downwards from last quarter.

  • Healthcare: BDT419.1bn (USD5.4bn) in 2015 to BDT460.8bn (USD5.8bn) in 2016; +9.9% in local currency terms and +7.6% in US dollar terms. Forecast unchanged from last quarter.

Headline Pharmaceuticals & Healthcare Forecasts (Bangladesh 2014-2020)
2014 2015 2016f 2017f 2018f 2019f 2020f
f = BMI forecast. Source: WHO, national sources, BMI
Pharmaceutical sales, USDbn 1.976 2.201 2.395 2.621 2.865 3.128 3.413
Pharmaceutical sales, % of GDP 1.14 1.13 1.09 1.07 1.05 1.02 1.00
Pharmaceutical sales, % of health expenditure 40.2 40.9 41.4 41.9 42.4 42.8 43.3
Health spending, USDbn 4.911 5.375 5.785 6.258 6.764 7.302 7.875

Risk/Reward Index

In Q117, Bangladesh's Risk/Reward Index (RRI) score remains unchanged from last quarter at 41.8 out of 100. Bangladesh also retains its ranking position in BMI's RRI matrix, standing as the 15th most attractive market to pharmaceutical investors out of 19 markets in the Asia Pacific region. Bangladesh's score is driven by a large pharmaceutical market (market expenditure score of 10.0 out of 20) and rapid drug market expansion (sector value growth score of 8.4 out of 12), but is dragged down by low levels of drug spending per capita (spending per capita score of 1.2 out of 12) and limited intellectual property protection (patent respect score of 1.4 out of 7).

Latest Updates

  • In September 2016, Bangladesh's minister of health, Mohammed Nasim, noted that the country is vulnerable to Zika. In particular, he noted that while there had not been any confirmed cases in the country yet, the Aedes mosquito is prevalent in Bangladesh. Nasim also alluded to the possibility of the disease spreading from neighbouring countries, highlighting that all countries in Asia are at risk.

  • In October 2016, Beacon Pharma signed a deal with Karellac, a Turkish-based drugmaker. Under the deal, the Bangladesh pharmaceutical firm will export anti-cancer and biotechnology medicines to Turkey.

BMI Economic View

In line with our view, Bangladesh Bank (BB) left its benchmark repo and reverse repo rates unchanged at 6.75% and 4.75%, respectively, during its July 2016 policy meeting, while pledging to maintain its selective easing measures. By allowing strategic sectors to access affordable loans, we believe that selective easing may support near-term growth, which we expect to come in at 6.5% y-o-y in 2016. However, increased credit growth will contribute to inflation risks.

BMI Political View

We have downgraded Bangladesh's short-term political risk index score to 61.0 from 62.7 previously, to reflect the intensification of Islamist violence and terrorist attacks in the country. We highlight that the situation could worsen over the coming months if the Awami League government continues to view the ongoing terrorist threats from the narrow prism of party politics, and denies the presence of foreign-linked Islamist terror groups in the country.

BMI Industry View
Table: Headline Pharmaceuticals & Healthcare Forecasts (Bangladesh 2014-2020)
Industry Forecast
Pharmaceutical Market Forecast
Table: Pharmaceutical Sales, Historical Data And Forecasts (Bangladesh 2012-2020)
Healthcare Market Forecast
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Bangladesh 2012-2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Bangladesh 2012-2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Bangladesh 2012-2020)
Prescription Drug Market Forecast
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Bangladesh 2012-2020)
Patented Drug Market Forecast
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Bangladesh 2012-2020)
Generic Drug Market Forecast
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Bangladesh 2012-2020)
OTC Medicine Market Forecast
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Bangladesh 2012-2020)
Pharmaceutical Trade Forecast
Table: Pharmaceutical Trade Data And Forecasts (Bangladesh 2014-2020)
Table: Pharmaceutical Trade Data And Forecasts local currency (Bangladesh 2014-2020)
Pharmaceuticals & Healthcare Risk/Reward Index
Asia Pacific Risk/Reward Index - Q3 2016
Bangladesh Risk/Reward Index
Regulatory Review
Table: Steps To Establish A Pharmaceutical Manufacturing Unit And Obtain A Drug Manufacturing Licence
Intellectual Property Issues
Pricing & Reimbursement Regime
Market Overview
Healthcare Sector
Table: Healthcare Resources (Bangladesh 2010-2015)
Table: Healthcare Personnel (Bangladesh 2010-2015)
Table: Healthcare Activity (Bangladesh 2010-2015)
Research & Development
Table: Suggestions Made By University Of Dhaka's Faculty Of Pharmacy To Improve Pharmaceutical Research
Clinical Trials
Competitive Landscape
Research-Based Industry
Table: Table: Multinational Market Activity
Pharmaceutical Distribution
Company Profile
Beximco Pharmaceuticals
Square Pharmaceuticals
Demographic Forecast
Table: Population Headline Indicators (Bangladesh 1990-2025)
Table: Key Population Ratios (Bangladesh 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Bangladesh 1990-2025)
Table: Population By Age Group (Bangladesh 1990-2025)
Table: Population By Age Group % (Bangladesh 1990-2025)
Pharmaceutical Expenditure Forecast Model
Healthcare Expenditure Forecast Model
Notes On Methodology
Risk/Reward Index Methodology
Index Overview
Table: Pharmaceutical Risk/Reward Index Indicators
Indicator Weightings

The Bangladesh Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Bangladesh Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Bangladesh pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Bangladesh, to test other views - a key input for successful budgeting and strategic business planning in the Bangladeshi pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Bangladeshi pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Bangladesh.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.


BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.